Bioprocessing of human neural stem/progenitor cells for the treatment of Parkinson's disease

用于治疗帕金森病的人类神经干/祖细胞的生物加工

• 批准号: 6583-2009
• 负责人: Behie, Leo
• 金额: $ 5.1万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2009
• 资助国家: 加拿大
• 起止时间: 2009-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=420273
• 关键词: Bioprocessing; human; neural; stem; progenitor

The Research Proposal I am putting forward in this NSERC Discovery Grant Application is very much a discovery project based on the bioprocessing of a type of human brain cell (i.e. adult stem harvested from somatic tissue) that I am now convinced will play a critically important role in a planned international clinical trial on Parkinson's disease. The first part of this clinical trial (i.e. based on stem cell therapy) will treat about 100 patients via transplantation of primary human tissue harvested from the ventral mesencephalon (VM) region of the human brain. The second stage of the clinical trial will use human brain cells produced using the bioreactor technology platform developed in my laboratory at the University of Calgary. The approach is a cell restorative strategy that focuses on restoring lost function by replacing the degenerated dopamine (DA)-producing neurons (DAergic neurons) using a transplantation procedure developed by a neurosurgeon colleague, Dr. Ivar Mendez, for the treatment of Parkinson's disease (PD).

我在这个NSERC发现资助申请中提出的研究建议是一个基于一种人类脑细胞生物加工的发现项目（即从体细胞组织中收获的成人干细胞），我现在相信它将在计划中的国际帕金森病临床试验中发挥至关重要的作用。这项临床试验的第一部分（即基于干细胞疗法）将通过移植从人脑腹侧中脑（VM）区域采集的原代人体组织来治疗约100名患者。临床试验的第二阶段将使用在卡尔加里大学我的实验室开发的生物反应器技术平台生产的人脑细胞。该方法是一种细胞恢复策略，其重点是通过使用神经外科医生同事Ivar Mendez博士开发的移植程序替换退化的多巴胺（DA）产生神经元（DA能神经元）来恢复失去的功能，用于治疗帕金森病（PD）。